In SHP77 small-cell lung cancer xenografts, carfilzomib monotherapy delayed tumor growth and prolonged survival versus vehicle. Adding cisplatin did not produce a significant survival advantage over vehicle, and two mice died during the first week of combination treatment; the authors judged these deaths likely drug-related. [2]
In PER-785 and PER-826 infant KMT2A-rearranged ALL xenografts, carfilzomib at the study-specific maximum tolerated dose of 2.0 mg/kg did not significantly prolong event-free survival versus vehicle. Dose finding in PER-785 mice showed toxicity at ≥2.5 mg/kg and early euthanasia at 4.0 mg/kg. These findings limit extrapolation across leukemia models. [3]
SHP77 xenograft efficacy and combination limits
Animal study · Female scid mice with established SHP77 small-cell lung cancer flank tumors; randomized at mean tumor volume 200–300 mm³; n = 8 per group. [2]
Carfilzomib monotherapy delayed tumor growth and prolonged survival versus vehicle. Cisplatin and the combination delayed growth without significant survival benefit versus vehicle. The combination produced two early deaths judged likely drug-related.
- Carfilzomib monotherapy
- Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
- Route: Intravenous
- Frequency: Two consecutive days each week.
- Treatment course: Continued until death or sacrifice; treatment began on day 20 in Figure 4.
- Vehicle: Composition of in vivo vehicle not specified in selected methods.
- Reported limits: No numerical tumor-growth inhibition percentage or median survival is extracted.
- Cisplatin monotherapy comparator
- Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
- Route: Intraperitoneal
- Frequency: Once weekly.
- Treatment course: 3 weeks.
- Vehicle: Cisplatin stock in saline; in vivo control vehicle composition not specified.
- Reported limits: Stock solvent does not establish composition of the matched in vivo control.
- Carfilzomib plus cisplatin
- Model: Female scid mice bearing SHP77 flank xenografts; n = 8 per group.
- Route: Carfilzomib intravenous; cisplatin intraperitoneal.
- Frequency: Carfilzomib on days 1 and 2 each week; cisplatin on day 5.
- Treatment course: Cisplatin for 3 weeks; carfilzomib schedule as in monotherapy.
- Vehicle: In vivo vehicle composition not specified in selected methods.
- Reported limits: No formal combination-versus-carfilzomib p value is supplied here; no synergy claimed.
Methods and source locations
Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: CFZ
Named-compound xenograft findings with a formulation-reproducibility limitation; no clinical or Adooq lot equivalence.
Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption
Survival of SHP77 tumor-bearing mice versus vehicle: Kaplan–Meier analysis; log-rank (Mantel–Cox) test; exact p values read from Figure 4B-D. Mice were euthanized at tumor volume 2000 mm³ or tumor necrosis. — Figure 4B-D; caption; Methods: In vivo SHP77 xenograft studies
Early deaths in combination-treated mice: Reported in Results as likely drug-related, not a mechanistically adjudicated cause of death. — Results: In vivo growth inhibition and survival
Carfilzomib monotherapy · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption
Cisplatin monotherapy comparator · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption
Carfilzomib plus cisplatin · Methods: In vivo SHP77 xenograft studies; Results: In vivo growth inhibition and survival; Figure 4A-D and caption
Dose finding and leukemia burden in PER-785 mice
Animal study · Female NOD/SCID mice bearing PER-785 infant KMT2A-rearranged ALL; randomized seven groups with nominal n = 5 per group. [3]
The authors selected 2.0 mg/kg as the maximum tolerated dose. Doses ≥2.5 mg/kg produced clinical toxicity; the 4.0 mg/kg group required early euthanasia. The measured leukemia burden was not reduced versus vehicle at the scheduled endpoint.
Conditions shared by the study groups
- Route
- Intravenous tail-vein injection.
- Carfilzomib dose range
- Model: Female NOD/SCID PER-785 xenografts; nominal n = 5 per dose group.
- Frequency: Days 1, 2, 8, 9, 15 and 16.
- Treatment course: 3 weeks; treatment commenced after a 12-day engraftment period.
- Vehicle: Aqueous Captisol or 2-hydroxypropyl-β-cyclodextrin; cohort assignment unspecified.
- Reported limits: Nominal n = 5 differs from visible plotted counts in some treated groups; do not infer exact attrition causes.
- High-dose tolerability limit
- Model: Female NOD/SCID PER-785 xenografts; nominal n = 5.
- Frequency: Planned days 1, 2, 8, 9, 15 and 16.
- Treatment course: Stopped before completion because of excessive morbidity.
- Vehicle: Aqueous cyclodextrin formulation; exact choice unspecified.
- Reported limits: Exact completed dose count and individual euthanasia times are not extracted; this group is not plotted in Figure 3.
Methods and source locations
Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib
Model-specific mouse findings; exact cyclodextrin assignment remains unknown. No salt conversion or Adooq material validation.
Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption
Dose-limiting morbidity: Clinical observation: ≥2.5 mg/kg caused weight loss, diarrhea, shortness of breath, slower movement and injection-site swelling; 4.0 mg/kg required euthanasia before treatment completion. — Results: Carfilzomib Displays Toxicity In Vivo...; Methods: Assessment of In Vivo Efficacy
Human CD19+CD45+ leukemia cells in bone marrow, spleen and peripheral blood: Flow cytometry 3 weeks after treatment began. Figure 3 depicts 1.5–3.5 mg/kg groups and vehicle; caption states n = 5 per group, while fewer points are visible in some treated groups. Error bars: mean ± SEM. — Figure 3 image/caption; Results toxicity section; Methods: Assessment of In Vivo Efficacy
Carfilzomib dose range · Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption
High-dose tolerability limit · Methods: Assessment of In Vivo Efficacy; Results: Carfilzomib Displays Toxicity In Vivo...; Figure 3 and caption
Low-burden infant-ALL xenograft survival
Animal study · Female NOD/SCID mice bearing PER-785 or PER-826 infant KMT2A-rearranged ALL; randomized carfilzomib and vehicle groups; n = 8 per group for each model. [3]
Carfilzomib at 2.0 mg/kg did not provide a significant event-free survival benefit over vehicle in either model.
Conditions shared by the study groups
- Route
- Intravenous tail-vein injection.
- Frequency
- Days 1, 2, 8, 9, 15 and 16.
- Vehicle
- Aqueous cyclodextrin formulation; exact choice unspecified.
- PER-785 monotherapy
- Model: Female NOD/SCID PER-785 xenografts; n = 8 per group.
- Treatment course: Started day 12 after cell injection, corresponding to 1% human CD19+CD45+ cells in bone marrow.
- Reported limits: No median or numerical p value extracted.
- PER-826 monotherapy
- Model: Female NOD/SCID PER-826 xenografts; n = 8 per group.
- Treatment course: Started day 18 after cell injection, corresponding to 1% human CD19+CD45+ cells in bone marrow.
- Reported limits: No median or numerical p value extracted.
Methods and source locations
Compound reported in the paper: Carfilzomib (PR-171); Compound label in the paper: carfilzomib
Model-specific mouse findings; exact cyclodextrin assignment remains unknown. No salt conversion or Adooq material validation.
Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption
Event-free survival in PER-785 and PER-826 xenografts: Log-rank test. Methods define individual EFS from treatment initiation to leukemia-related humane endpoint; Figure 4 axes instead display days post injection. No exact p value or median survival digitized. — Figure 4A,B image/caption; Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section
PER-785 monotherapy · Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption
PER-826 monotherapy · Methods: Assessment of In Vivo Efficacy and Statistical Analyses; Results toxicity/efficacy section; Figure 4A,B and caption